Stock listing
OTC:EGRX Eagle Pharmaceuticals, Inc. Stock
Follow Eagle Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:EGRX
$0.65 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.40 – $0.65 USDNov 20, 2026
- Volume
- 275 sharesNov 20, 2026
- Market cap
- $8.55M USDAt the close on Nov 20, 2026 · price × 13.16M shares outstanding
- 52-week range
- $0.0010 – $3.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1,491 USDMedian day 0 shares · 38 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:EGRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.65 | 0.00 | 0.0% | $0.40 | $0.65 | $0.40 | 275 | |
| $0.65 | 0.00 | 0.0% | $0.65 | $0.65 | $0.65 | 0 | |
| $0.65 | -0.25 | -27.8% | $0.45 | $0.65 | $0.45 | 2,400 | |
| $0.90 | +0.08 | +9.8% | $0.21 | $0.90 | $0.21 | 500 | |
| $0.82 | 0.00 | 0.0% | $0.82 | $0.82 | $0.82 | 0 | |
| $0.82 | 0.00 | 0.0% | $0.82 | $0.82 | $0.82 | 0 | |
| $0.82 | 0.00 | 0.0% | $0.82 | $0.82 | $0.82 | 0 | |
| $0.82 | -0.08 | -8.9% | $0.25 | $0.86 | $0.25 | 900 | |
| $0.90 | -0.05 | -5.3% | $0.21 | $0.90 | $0.21 | 300 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.95 | $0.95 | 0 | |
| $0.95 | -0.05 | -5.0% | $0.0020 | $0.975 | $0.0020 | 3,900 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 0 | |
| $1.00 | -2.935 | -74.6% | $0.95 | $1.00 | $0.95 | 200 | |
| $3.935 | +3.05 | +344.6% | $0.70 | $3.935 | $0.70 | 1,600 | |
| $0.885 | 0.00 | 0.0% | $0.885 | $0.885 | $0.885 | 0 | |
| $0.885 | 0.00 | 0.0% | $0.885 | $0.885 | $0.885 | 0 | |
| $0.885 | +0.005 | +0.6% | $0.60 | $0.885 | $0.60 | 4,900 | |
| $0.88 | 0.00 | 0.0% | $0.88 | $0.88 | $0.88 | 0 | |
| $0.88 | -0.005 | -0.6% | $0.11 | $0.88 | $0.11 | 4,300 | |
| $0.885 | -0.085 | -8.8% | $0.181 | $0.885 | $0.181 | 3,300 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | 0.00 | 0.0% | $0.97 | $0.97 | $0.97 | 0 | |
| $0.97 | +0.01 | +1.0% | $0.21 | $0.97 | $0.21 | 1,400 | |
| $0.96 | +0.01 | +1.1% | $0.75 | $0.96 | $0.665 | 3,500 | |
| $0.95 | -0.075 | -7.3% | $0.18 | $0.975 | $0.18 | 7,300 | |
| $1.025 | 0.00 | 0.0% | $1.025 | $1.025 | $1.025 | 0 | |
| $1.025 | 0.00 | 0.0% | $1.025 | $1.025 | $1.025 | 0 | |
| $1.025 | +0.125 | +13.9% | $0.975 | $1.025 | $0.975 | 16,000 | |
| $0.90 | 0.00 | 0.0% | $0.90 | $0.90 | $0.90 | 4,100 | |
| $0.90 | 0.00 | 0.0% | $0.18 | $0.90 | $0.18 | 300 | |
| $0.90 | 0.00 | 0.0% | $0.90 | $0.90 | $0.90 | 0 | |
| $0.90 | -0.385 | -30.0% | $0.40 | $0.90 | $0.40 | 3,500 | |
| $1.285 | 0.00 | 0.0% | $1.285 | $1.285 | $1.285 | 0 | |
| $1.285 | 0.00 | 0.0% | $1.285 | $1.285 | $1.285 | 0 | |
| $1.285 | 0.00 | 0.0% | $1.285 | $1.285 | $1.285 | 0 | |
| $1.285 | 0.00 | 0.0% | $1.285 | $1.285 | $1.285 | 0 | |
| $1.285 | +0.53 | +70.2% | $0.18 | $1.285 | $0.18 | 800 | |
| $0.755 | +0.005 | +0.7% | $0.18 | $0.755 | $0.18 | 5,900 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | -0.165 | -18.0% | $0.17 | $0.90 | $0.17 | 1,100 | |
| $0.915 | -0.01 | -1.1% | $0.40 | $0.915 | $0.40 | 16,100 | |
| $0.925 | 0.00 | 0.0% | $0.925 | $0.925 | $0.925 | 0 | |
| $0.925 | 0.00 | 0.0% | $0.925 | $0.925 | $0.925 | 0 | |
| $0.925 | 0.00 | 0.0% | $0.925 | $0.925 | $0.925 | 0 | |
| $0.925 | +0.24 | +35.0% | $0.18 | $0.925 | $0.18 | 10,300 | |
| $0.685 | +0.155 | +29.2% | $0.37 | $0.685 | $0.37 | 3,800 | |
| $0.53 | 0.00 | 0.0% | $0.53 | $0.53 | $0.53 | 0 | |
| $0.53 | 0.00 | 0.0% | $0.53 | $0.53 | $0.53 | 0 | |
| $0.53 | 0.00 | 0.0% | $0.53 | $0.53 | $0.53 | 0 | |
| $0.53 | -0.065 | -10.9% | $0.15 | $0.53 | $0.15 | 2,200 |
- Ticker
- OTC:EGRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 30, 2026
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
Latest news
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
Oct 30, 2026
Closed $0.95 (0.0%) on Oct 30, 2026
Eagle Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 1 in the last 12 months · 1 in all · newest Oct 30, 2026 · oldest 2026
- Calls
- 12 calls with a replay · 12 with a transcript · latest Aug 8, 2023
- Decks
- 47 decks · latest Sep 27, 2023
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.20
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. · OTC:EGRX | US$8.55M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.20 |
| PT Phapros Tbk · IDX:PEHA | US$12.79M | US$41.58M | 4.5× | 0.7× | 4.6× | 0.5× | 5.0% | 1.5× | n/a |
| PT Ikapharmindo Putramas Tbk · IDX:IKPM | US$11.81M | US$10.76M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Alpa Laboratories Limited · NSE:ALPA | US$11.33M | US$11.33M | 24.0× | 0.9× | 12.2× | 0.6× | 3.8% | 0.0× | n/a |
| Advicenne SA · EURONEXT:ALDVI | US$10.53M | US$32.08M | n/a | 4.9× | n/a | n/a | −158.7% | n/a | n/a |
| Biofrontera Inc. · NASDAQ:BFRI | US$9.51M | US$13.83M | n/a | 0.3× | n/a | n/a | −12.7% | n/a | 1.96 |
| Optimi Health Corp. · CSE:OPTI | US$9.18M | US$67,058 | n/a | 0.6× | n/a | 0.8× | n/a | 0.0× | 1.08 |
| ChoA Pharmaceutical Co., Ltd. · KRX:034940 | US$6.59M | US$6.89M | n/a | 0.1× | n/a | 0.3× | −4.6% | 0.1× | n/a |
| Newbury Pharmaceuticals AB · OMXSTO:NEWBRY | US$5.78M | US$4.87M | n/a | 1.2× | n/a | 3.0× | −53.7% | 0.0× | n/a |
| Firebrick Pharma Limited · ASX:FRE | US$5.51M | US$4.63M | n/a | 66.0× | n/a | 5.0× | n/a | 0.0× | n/a |
| Universe Pharmaceuticals INC · NASDAQ:UPC | US$5.41M | −US$14.09M | n/a | 0.0× | n/a | 0.1× | −20.6% | 0.2× | 0.91 |
| Median of the others | US$9.35M | US$8.83M | 14.2× | 0.7× | 8.4× | 0.7× | −12.7% | 0.0× | 1.08 |
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Graves | Chairman of the Board, Chief Executive Officer |
| Christopher Krawtschuk | Chief Financial Officer |
| Daniel O’Connor | Chief Strategy Officer, Head of Corporate Development |
Board
| Director | Role |
|---|---|
| Michael Graves | Chairman of the Board, Chief Executive Officer |
| Jennifer Simpson | Board Member, Lead Independent Director of the Board |
| Luciana Borio | Board Member, Strategic Clinical Development Committee Chair |
| Richard A. Edlin | Board Member |
| Robert L. Glenning | Board Member, Audit Committee Chair |
| Steven Ratoff | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Eagle Pharmaceuticals (OTC:EGRX) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q1 2023 Earnings Call | Tue, May 09, 2023 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q4 2022 Earnings Call | Mon, Mar 13, 2023 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q3 2022 Earnings Call | Mon, Nov 07, 2022 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q1 2022 Earnings Call | Mon, May 09, 2022 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q4 2021 Earnings Call | Mon, Mar 07, 2022 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q1 2021 Earnings Call | Mon, May 10, 2021 · 8:30 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Eagle Pharmaceuticals (OTC:EGRX) Q4 2020 Earnings Call | Tue, Mar 02, 2021 · 8:30 AM ET | Replay |
| Eagle Pharmaceuticals (OTC:EGRX) Q3 2020 Earnings Call | Mon, Nov 02, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | May 11, 2026 | −1.3% |
| Quarter to Dec 31, 2025 | Mar 9, 2026 | +127.3% |
| Quarter to Sep 30, 2025 | Oct 16, 2025 | 0.0% |
| Quarter to Jun 30, 2025 | Aug 29, 2025 | +0.2% |
| Quarter to Mar 31, 2025 | May 30, 2025 | +5.3% |
| Quarter to Dec 31, 2024 | Mar 10, 2025 | +21.2% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | +5.6% |
| Quarter to Jun 30, 2024 | Aug 6, 2024 | −2.5% |
| Quarter to Mar 31, 2024 | May 7, 2024 | +3.9% |
| Quarter to Dec 31, 2023 | Feb 28, 2024 | −9.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2023 | Dec 8, 2023 · Before open | −2.7% |
| Q2 2023 | Aug 8, 2023 · Before open | +4.9% |
| Q1 2023 | May 9, 2023 · Before open | −13.3% |
| Q4 2022 | Mar 13, 2023 · Before open | +1.8% |
| Q3 2022 | Nov 7, 2022 · Before open | +25.9% |
| Q2 2022 | Aug 9, 2022 · Before open | −14.5% |
| Q1 2022 | May 9, 2022 · Before open | −0.7% |
| Q4 2021 | Mar 7, 2022 · Before open | +5.9% |
| Q3 2021 | Nov 9, 2021 · Before open | +0.6% |
| Q2 2021 | Aug 9, 2021 · Before open | +4.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2023) | Investor deck | 21 slides | Sep 27, 2023 |
| Investor Presentation (September 2023) | Investor deck | 20 slides | Sep 7, 2023 |
| Investor Presentation (June 2023) | Investor deck | 16 slides | Jun 7, 2023 |
| J.P. Morgan Healthcare Conference January 2023 | Conference | 14 slides | Jan 10, 2023 |
| J.P. Morgan Healthcare Conference January 2023 | Conference | 14 slides | Jan 9, 2023 |
| Investor Day (December 2022) | Investor day | 144 slides | Dec 6, 2022 |
| Investor Presentation (June 2022) | Investor deck | 10 slides | Jun 9, 2022 |
| Merger or Acquisition (March 2022) | Merger or acquisition | 32 slides | Mar 31, 2022 |
| Investor Presentation (January 2022) | Investor deck | 29 slides | Jan 11, 2022 |
| Investor Presentation (October 2021) | Investor deck | 32 slides | Oct 14, 2021 |
All 47 decks
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 316.6M | 171.5M | 187.8M | 195.9M | 213.3M | 236.7M | 189.5M | 66.2M | 19.1M | 13.7M |
| Cost of revenue | 94.9M | 42.2M | 45.5M | 60.9M | 61.9M | 57.2M | 55.3M | 15.6M | 11.7M | 7.38M |
| Gross profit | 221.7M | 129.4M | 142.3M | 135.0M | 151.4M | 179.5M | 134.2M | 50.6M | 7.38M | 6.30M |
| Research and development | 34.1M | 51.3M | 30.8M | 36.8M | 44.4M | 32.6M | 30.3M | 27.9M | 16.8M | 9.80M |
| Selling, general and administrative | 98.1M | 66.8M | 75.9M | 74.0M | 57.2M | 73.1M | 37.5M | 15.4M | 5.02M | 14.8M |
| Operating income | 81.0M | 2.77M | 33.0M | 21.8M | 36.6M | 74.0M | 53.4M | 2.56M | -18.8M | -8.46M |
| Depreciation and amortization | 12.0M | 3.76M | 4.77M | 4.65M | 3.67M | 3.75M | 1.59M | 112.0K | 104.0K | 135.0K |
| EBITDA | 93.0M | 6.53M | 37.7M | 26.5M | 40.3M | 77.7M | 54.9M | 2.67M | -18.7M | -8.32M |
| Interest expense | 4.04M | 1.64M | 2.58M | 2.69M | 2.74M | 1.14M | 8.00K | 11.0K | 8.00K | 1.40M |
| Income before tax | 61.4M | -4.55M | 22.7M | 22.0M | 34.0M | 72.9M | 53.4M | 2.57M | -19.3M | -6.95M |
| Income tax | 25.8M | 4.08M | 10.7M | 7.68M | 2.13M | 21.0M | -28.0M | 3.00K | -1.29M | -898.7K |
| Net income | 35.6M | -8.63M | 12.0M | 14.3M | 31.9M | 51.9M | 81.5M | 2.57M | -18.0M | -6.05M |
| Earnings per share, basic | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 | 3.27 | 4.96 | 0.16 | -1.81 | -0.57 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 55.3M | 97.7M | 103.2M | 109.8M | 78.8M | 114.7M | 52.8M | 79.1M | 22.7M | 10.5M |
| Short-term investments | 4.98M | 0 | 0 | 0 | 20.0M | |||||
| Receivables | 73.4M | 41.5M | 51.1M | 48.0M | 66.5M | 53.8M | 42.2M | 26.3M | 7.30M | 5.12M |
| Inventory | 47.8M | 21.9M | 8.07M | 6.57M | 8.30M | 5.12M | 2.74M | 15.0M | 1.29M | 1.87M |
| Current assets | 188.8M | 172.6M | 166.1M | 179.4M | 163.8M | 188.7M | 109.1M | 122.3M | 53.0M | 17.5M |
| Property, plant and equipment | 1.17M | 1.64M | 2.08M | 2.20M | 2.40M | 6.82M | 3.32M | 2.21M | 344.0K | 402.0K |
| Goodwill | 45.0M | 39.7M | 39.7M | 39.7M | 39.7M | 39.7M | 39.7M | 0 | 39.7M | |
| Total assets | 406.2M | 253.7M | 253.2M | 254.6M | 238.6M | 270.1M | 213.6M | 124.6M | 53.4M | 18.1M |
| Accounts payable | 19.0M | 16.4M | 6.27M | 5.46M | 9.92M | 12.0M | 14.7M | 3.94M | 4.06M | 1.19M |
| Current liabilities | 111.1M | 74.4M | 38.1M | 38.8M | 39.7M | 47.3M | 40.2M | 34.3M | 20.3M | 14.3M |
| Long-term debt | 56.2M | 25.1M | 33.6M | 38.2M | 42.9M | 0 | 0 | 0 | 1.71M | |
| Total debt | 67.8M | 29.8M | 38.2M | 38.6M | 44.4M | 47.8M | ||||
| Total liabilities | 172.6M | 77.3M | 67.2M | 75.4M | 77.8M | 90.9M | 62.3M | 34.3M | 20.3M | 16.0M |
| Shareholders' equity | 233.6M | 176.5M | 186.0M | 179.2M | 160.8M | 179.1M | 151.2M | 90.3M | 33.1M | 2.05M |
| Shares outstanding | 13.1M | 13.1M | 13.8M | 14.1M | 15.3M | 15.9M | 16.4M | 16.3M | 9.96M | 10.6M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 50.7M | 28.2M | 49.5M | 56.0M | 52.4M | 58.9M | 53.2M | -9.72M | -13.8M | -5.88M |
| Capital spending | -178.0K | -323.0K | -747.0K | -777.0K | -133.0K | -5.19M | -20.7M | -1.88M | -46.0K | -40.5K |
| Free cash flow | 50.5M | 27.9M | 48.8M | 55.2M | 52.3M | 53.7M | 32.5M | -11.6M | -13.9M | -5.92M |
| Cash from investing | -86.8M | -5.32M | -18.2M | -777.0K | -133.0K | -5.19M | -45.8M | -1.88M | -20.0M | 1.46M |
| Cash from financing | -6.21M | -28.4M | -37.9M | -24.2M | -88.1M | 8.10M | -33.7M | 55.8M | 46.2M | 9.81M |
| Dividends paid | -1.75M | -2.40M | -3.65M | -260.0K | 0 | 0 | 0 | 0 | ||
| Share buybacks | -18.0M | -21.2M | -35.0M | -18.0M | -73.1M | -43.8M | -37.0M | 55.8M | 46.2M | |
| Change in cash | -42.3M | -5.50M | -6.62M | 31.0M | -35.9M | 61.8M | -26.3M | 44.2M | 12.3M | 5.39M |
Cap table
Built by 6ix from Eagle Pharmaceuticals, Inc.’s releases
- Common shares
- 13,157,553
- Fully diluted
- 13,157,553
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,157,553 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,157,553 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Douglas L Braunstein Other companies: Talkspace, Inc. (Director · Since at least Jun 22, 2021); Hudson Executive Investment Corp II (Director · Mar 11, 2021 – Feb 7, 2022 · Past); Hudson Executive Investment Corp III (Director · Feb 23, 2021 – Mar 2, 2022 · Past); Cardtronics plc (Director · Aug 8, 2018 – Jun 25, 2020 · Past); Corindus Vascular Robotics Inc (Director · Mar 16, 2018 – Oct 29, 2019 · Past); JPMorgan Chase & Co. (Chief Financial Officer · Jun 22, 2010 – Dec 17, 2012 · Past) | Director · Jul 5, 2016 – Oct 24, 2019 · Past |
| Jennifer Simpson Other companies: LadRx Corporation (Director · Jan 15, 2024 – Jan 15, 2024 · Past); Panbela Therapeutics, Inc. (President and CEO, Director · Mar 30, 2021 – Oct 1, 2024 · Past); Delcath Systems, Inc. (President and CEO, Director · Mar 23, 2012 – May 6, 2020 · Past) | Board Member, Lead Independent Director of the Board · Since at least Aug 28, 2019 |
| Sander A Flaum Other companies: Viasys Healthcare Inc (Director · May 11, 2006 – Jun 28, 2007 · Past) | Director · Feb 11, 2014 – Mar 5, 2019 · Past |
| Brian Joseph Cahill | CHIEF FINANCIAL OFFICER · Oct 29, 2020 – Feb 27, 2024 · Past |
| Christopher Krawtschuk | Chief Financial Officer · Since at least Nov 5, 2026 |
| Daniel O’Connor | Chief Strategy Officer, Head of Corporate Development · Since at least Nov 5, 2026 |
| David E Riggs | Chief Financial Officer · Feb 11, 2014 – Jan 4, 2017 · Past |
| Luciana Borio | Board Member, Strategic Clinical Development Committee Chair · Since at least Nov 5, 2026 |
| Michael Graves | Chairman of the Board, Chief Executive Officer · Since at least Feb 11, 2014 |
| Richard A. Edlin | Board Member · Since at least Nov 5, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Robert L. Glenning | Board Member, Audit Committee Chair · Since at least Jul 5, 2016 |
| Steven B Ratoff | Director · Jan 4, 2016 – Mar 7, 2023 · Past |
| Steven L Krill | EVP & Chief Scientific Officer · Feb 11, 2014 – Jan 7, 2018 · Past |
| Steven Ratoff | Board Member · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Eagle Pharmaceuticals, Inc.